WAYNE, Pa.--(BUSINESS WIRE)--The current and emerging technologies for detecting and characterizing human leukocyte antigen (HLA) alloantibodies provide powerful tools for predicting the risk of immunological response to a transplant. By standardizing methods, quality control, and clinical interpretations, transplant centers can more readily identify optimal donor recipient pairs and encourage organ sharing.
